Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

Gavin Giovannoni; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Anthony Hamlett; Vissia Viglietta; Steven Greenberg; CLARITY Study Group

doi:10.1016/S1474-4422(11)70023-0

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

Gavin Giovannoni, Stuart Cook, Kottil Rammohan, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Anthony Hamlett, Vissia Viglietta, Steven Greenberg, CLARITY Study Group

Afdeling for Hjerne- og Nervesygdomme

213 Citationer (Scopus)

Abstract

On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.

Originalsprog	Engelsk
Tidsskrift	Lancet neurology
Vol/bind	10
Udgave nummer	4
Sider (fra-til)	329-37
Antal sider	9
ISSN	1474-4422
DOI	https://doi.org/10.1016/S1474-4422(11)70023-0
Status	Udgivet - 2011

Adgang til dokumentet

10.1016/S1474-4422(11)70023-0

Citationsformater

Giovannoni, G., Cook, S., Rammohan, K., Rieckmann, P., Sørensen, P. S., Vermersch, P., Hamlett, A., Viglietta, V., Greenberg, S., & CLARITY Study Group (2011). Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet neurology, 10(4), 329-37. https://doi.org/10.1016/S1474-4422(11)70023-0

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. / Giovannoni, Gavin; Cook, Stuart; Rammohan, Kottil et al.
I: Lancet neurology, Bind 10, Nr. 4, 2011, s. 329-37.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Giovannoni, G, Cook, S, Rammohan, K, Rieckmann, P, Sørensen, PS, Vermersch, P, Hamlett, A, Viglietta, V, Greenberg, S & CLARITY Study Group 2011, 'Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis', Lancet neurology, bind 10, nr. 4, s. 329-37. https://doi.org/10.1016/S1474-4422(11)70023-0

@article{46922ab0ad1a4440bd457204828c7922,

title = "Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis",

abstract = "On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.",

keywords = "Cladribine, Disease-Free Survival, Humans, Immunosuppressive Agents, Multiple Sclerosis, Relapsing-Remitting, Odds Ratio, Randomized Controlled Trials as Topic, Treatment Outcome",

author = "Gavin Giovannoni and Stuart Cook and Kottil Rammohan and Peter Rieckmann and S{\o}rensen, {Per Soelberg} and Patrick Vermersch and Anthony Hamlett and Vissia Viglietta and Steven Greenberg and {CLARITY Study Group}",

year = "2011",

doi = "10.1016/S1474-4422(11)70023-0",

language = "English",

volume = "10",

pages = "329--37",

journal = "Lancet neurology",

issn = "1474-4422",

publisher = "Elsevier Limited",

number = "4",

}

TY - JOUR

T1 - Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

AU - Giovannoni, Gavin

AU - Cook, Stuart

AU - Rammohan, Kottil

AU - Rieckmann, Peter

AU - Sørensen, Per Soelberg

AU - Vermersch, Patrick

AU - Hamlett, Anthony

AU - Viglietta, Vissia

AU - Greenberg, Steven

AU - CLARITY Study Group

PY - 2011

Y1 - 2011

N2 - On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.

AB - On the basis of various clinical and MRI measurements, the phase 3 Cladribine Tablets Treating Multiple Sclerosis Orally (CLARITY) study in patients with relapsing-remitting multiple sclerosis (RRMS) showed that short-course oral treatment with cladribine at cumulative doses of 3·5 and 5·25 mg/kg over 96 weeks was more effective than placebo. Achieving sustained freedom from disease activity is becoming a viable treatment goal in RRMS; we therefore aimed to assess the effects of cladribine on this composite outcome measure by doing a post-hoc analysis of data from the CLARITY study.

KW - Cladribine

KW - Disease-Free Survival

KW - Humans

KW - Immunosuppressive Agents

KW - Multiple Sclerosis, Relapsing-Remitting

KW - Odds Ratio

KW - Randomized Controlled Trials as Topic

KW - Treatment Outcome

U2 - 10.1016/S1474-4422(11)70023-0

DO - 10.1016/S1474-4422(11)70023-0

M3 - Journal article

C2 - 21397565

SN - 1474-4422

VL - 10

SP - 329

EP - 337

JO - Lancet neurology

JF - Lancet neurology

IS - 4

ER -

Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater